2.790USDMkt Cap: 93.54M USDP/E: —Last update: 2026-05-22
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a ch…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap93.54M USD
Enterprise Value76.96M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.93M USD
Revenue/Share—
Last Price2.790 USD
Fiscal Year EndOct 2025
MR QuarterJan 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS03528H1095
Valuation
P/E (Trailing)—
P/E (Forward)-7.64
PEG-0.11
EV/EBITDA—
EV/Revenue—
P/S—
P/B6.10
EPS (TTM)-0.32
EPS (Forward)-0.36
52W Range
2.75554% of range2.820
52W High2.820 USD
52W Low2.755 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.07%
ROA-67.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.17M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-3.73%
Net Debt-14.01M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.01
Current Ratio12.18
Quick Ratio11.49
Book Value/Sh0.4510 USD
Cash/Share0.4240 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 26, 2015
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)10.75 USD
Target Range9.000 USD – 14.00 USD
# Analysts4
Ownership
Shares Out.33.53M
Float31.72M
Insiders5.38%
Institutions15.46%
Short Interest
Short Ratio8.8d
Short % Float3.26%
Short % Out.3.09%
Shares Short1.04M
Short (prev mo.)1.15M
Technical
SMA 502.831 (-1.5%)
SMA 2003.341 (-16.5%)
Beta0.65
S&P 52W Chg28.31%
Avg Vol (30d)40.45K
Avg Vol (10d)103.81K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—